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Until recently, the salt debate remained dominated by a 
select group of highly vocal global leaders whose goal is to 
impose their views through an unbalanced interpretation of 
so-called compelling evidence. Sailing against the tide, in 
this issue of the Journal, Graudal and colleagues published 
a comprehensive review of the literature1 that complied 
with the highest possible quality standards as proposed by 
the Meta-analysis of Observational Studies in Epidemiology 
group.2 Data from 23 cohort studies and 2 follow-up studies 
of randomized controlled trials (n  =  274,683 participants) 
showed that the risks of all-cause mortality or cardiovascular 
disease were higher at low and high vs. usual sodium intake, 
congruent with a U-shaped association between health out-
comes and salt intake.1 The hazard ratios of total mortality 
and cardiovascular disease for low vs. usual sodium intake 
were 1.10 (95% confidence interval (CI)  =  1.01–1.22) and 
1.11 (95% CI = 1.01–1.22), respectively. The corresponding 
hazard ratios for high vs. usual sodium exposure were 1.16 
(95% CI = 1.03–1.30) and 1.12 (95% CI = 1.02–1.24).1
Cardiovascular endpoints and 24-hour urinary sodium
Graudal et al.’s findings are in line with our cohort study in 
European populations published in 2011.3 Nearly 90% of the 
world’s populations have a mean usual sodium intake rang-
ing from 115 to 215 mmol per day.4 This range nearly cor-
responds with the mean values of 24-hour urinary sodium 
excretion in the low (107 mmol) and high (260 mmol) thirds 
of the distribution in European populations.3 Moreover, 
Graudal et  al. reported that in population-representative 
samples adjusted for multiple confounders the risk of all-
cause mortality was higher at low vs. usual sodium intake 
but not at high vs. usual sodium intake, with hazard ratios 
of 1.16 (95% CI = 1.09–1.23) and 0.96 (95% CI = 0.84–1.10), 
respectively.1 Among our 3,681 participants followed up 
for a median 7.9 years, all-cause mortality was not related 
to urinary sodium, but cardiovascular mortality decreased 
across increasing tertiles of 24-hour urinary sodium excre-
tion, from 50 deaths in the low excretion group, to 24 in the 
medium excretion group (mean = 168 mmol), to 10 in the 
high excretion group, resulting in respective death rates of 
4.1%, 1.9%, and 0.8%. In multivariable-adjusted analyses, 
this inverse association retained significance (P = 0.02); the 
hazard ratios expressing the risk of a cardiovascular death 
in the low, medium, and high tertiles were 1.56, 1.05, and 
0.96, respectively (P for linear trend = 0.02).3 Among 2,096 
participants followed up for 6.5 years, the risk of hyperten-
sion did not increase across increasing tertiles (P = 0.93).3 In 
1,499 participants followed up for 6.1 years, systolic blood 
pressure increased by 0.37 mm Hg per year (P  <  0.001), 
whereas sodium excretion did not change (−0.45 mmol per 
year; P  =  0.15). In multivariable-adjusted analyses, a 100-
mmol increase in sodium excretion was associated with a 
1.7–mm Hg increase in systolic blood pressure (P < 0.001) 
with no difference in diastolic blood pressure.3 The sys-
tolic estimate approximated to the effects associated with a 
75-mmol change in 24-hour urinary sodium in meta-analy-
ses of sodium intervention studies in normotensive subjects, 
reportedly ranging from 2.0 mm Hg5 to 2.4 mm Hg.6
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Even before our article3 was brought out in print, The 
Lancet found it necessary to publish an unsigned edito-
rial warning that our study was flawed.7 The editorial cited 
Peter Briss, a medical director of the US Centers for Disease 
Control and Prevention, who qualified our study as being 
small with low event rates and relatively young partici-
pants.7 Walter Willett, Chair of the Department of Nutrition 
at Harvard School of Public Health, also pointed out other 
weaknesses—unreliable measurement of sodium intake, fail-
ure to account for key factors that influence sodium intake 
and heart disease risk, and missing or incomplete urine data 
from large numbers of participants.7 We answered these 
criticisms in the correspondence section of the Journal of 
American Medical Association.8 As reviewed elsewhere9 and 
in keeping with Graudal et al.’s meta-analysis,1 several stud-
ies subsequently noticed an inverse association or a J-shaped 
relation between mortality10,11 or cardiovascular disease12,13 
and urinary sodium. Nevertheless, we and other investi-
gators remained the target of heavy flak.14–16 On the other 
hand, we also received letters of support from several experts 
in the field.17
Review of the “compelling” evidence
The Lancet went on to state that our study was disappoint-
ingly weak and contributed little to the understanding of salt 
and disease.7 It was likely to confuse public perceptions of 
the importance of salt as a risk factor for high blood pres-
sure, heart disease, and stroke. Questions of intervention 
and outcome, such as sodium intake and cardiovascular dis-
ease events, cannot be answered by small observational stud-
ies. We therefore found it useful to read beyond the abstract 
of some of the papers that are part of the so-called compel-
ling evidence supporting a drastic reduction of salt intake 
in the general population below the current usual level of 
115–215 mmol per day.4 In INTERSALT, the within-center 
analyses demonstrated an inconsistent association between 
systolic blood pressure and 24-hour urinary sodium excre-
tion, with both significantly positive and inverse associa-
tions.18 The between-center analysis showed an effect size 
of 7.1 mm Hg per 100  mmol sodium across 52 centers 
(P < 0.001), which weakened to 2.8 mm Hg per 100 mmol 
after exclusion of 4 primitive societies with extreme low 
urinary sodium output.18 Notably, the methodology to col-
lect 24-hour urine samples was similar in INTERSALT18 
and in our population studies,3,19 and the average values of 
24-hour urinary sodium were similar in our studies3,19 and 
the Belgian (Gent and Charleroi), Polish (Kraków), and 
Russian (Novosibirsk) INTERSALT centers.20 Moreover, the 
between-center INTERSALT analysis is an aggregate-level 
ecological meta-analysis that is vulnerable to demonstrat-
ing spurious associations.21,22 A  Finnish population study 
with a sample size (n = 2436), smaller than ours is part of the 
compelling evidence.23 In the summary of their article,23 the 
authors concluded: “High sodium intake predicted mortal-
ity and risk of coronary heart disease, independent of other 
cardiovascular risk factors, including blood pressure. These 
results provide direct evidence of the harmful effects of high 
salt intake in the adult population.” However, among 1,263 
women, none of the fully adjusted hazard ratios relating 
fatal outcomes, coronary heart disease, or stroke to 24-hour 
urinary sodium reached significance.23 Among 1,173 men, 
the hazard ratios were significant for fatal outcomes and 
coronary heart disease but not for stroke, the complica-
tion of hypertension most closely related to blood pres-
sure.24 Moreover, subgroup analyses demonstrated that the 
association between mortality and 24-hour urinary sodium 
reached significance only among 514 obese men,23 whereas 
for women no analysis stratified for body mass index was 
reported.
Yang and colleagues analyzed 12,267 adults included 
in the Third National Health and Nutrition Examination 
Survey Linked Mortality File (1988–2006).25 The abstract 
closed by stating that a higher sodium-to-potassium ratio 
was associated with a significantly increased risk of car-
diovascular disease and all-cause mortality. However, in 
multivariable-adjusted analyses, the risk of cardiovascular 
mortality (n = 825) and death from ischemic heart disease 
(n = 443) was not significantly associated with usual sodium 
intake but was inversely related with potassium ingestion, 
explaining the positive correlation with the sodium-to-
potassium ratio. With adjustments applied, all-cause mortal-
ity (n = 2,270) was positively associated with usual sodium 
intake but inversely associated with potassium consumption, 
suggesting that not cardiovascular disease or blood pressure, 
but instead noncardiovascular mortality, could have driven 
the association between total mortality and usual sodium 
intake.
The investigators of the Trial of Nonpharmacologic 
Interventions in the Elderly (TONE) also contributed to 
the compelling evidence. They enthusiastically concluded 
that the TONE results had important implications both 
for public health professionals and clinical practitioners.26 
They proposed that older patients with hypertension were 
able to make and sustain lifestyle changes and that these 
“impressive” results were obtained in the context of mod-
erate reductions in sodium consumption.26 However, 8,787 
patients had to be screened to randomize a highly selected 
group of 11.1%.26 The reduction in 24-hour urinary sodium 
in participants assigned to salt restriction averaged approxi-
mately 40 mmol/day (920 mg/day), resulting in a decrease 
in blood pressure averaging 3.5 mm Hg systolic and 1.9 mm 
Hg diastolic. Furthermore, sodium restriction reduced the 
risk of a primary endpoint by 31%, but the primary endpoint 
consisted mainly of weak outcomes, such as high blood 
pressure after discontinuation of antihypertensive drugs, 
resuming antihypertensive drug treatment, and inability to 
withdraw blood pressure–lowering treatment. There was no 
significant between-group difference in what really matters, 
the occurrence of cardiovascular complications, such as 
angina, myocardial infarction, stroke, or coronary revascu-
larization (P ≥ 0.16).26 However, a similar trend of a lower 
incidence of adverse health outcomes was observed in the 
follow-up of Trials of Hypertension Prevention (TOHP) 
I and II participants randomized to a reduction of sodium 
intake or usual care.27
In a meta-analysis of studies relating cardiovascu-
lar outcomes to sodium intake, Strazzullo and colleagues 
concluded in the summary: “High salt intake is associ-
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cardiovascular disease.”28 The risk of stroke increased by 
6% (95% CI = 3%–10%; P = 0.04) for an increase in sodium 
intake by 50 mmol per day.28 A similar trend for cardiovas-
cular disease was not significant (19%; 95% CI = −31% to 
107%; P = 0.53). Across the reports included in Strazzullo’s 
meta-analysis, the methods for assessing salt intake were not 
standardized.29 Studies with exclusively fatal outcomes were 
pooled with those including both fatal and nonfatal events. 
Moreover, the hazard ratios used in the variance-weighted 
meta-regression analysis were not standardized to the 
same amount of sodium.29 In contrast with Graudal et al.,1 
Strazzullo and colleagues compared the highest category 
with the lowest category, assuming a linear association over 
the whole range of sodium intake.28
The long-term observational follow-up of TOHP I  and 
II27,30,31 also generated compelling evidence. In the most 
recent report, among 2,275 prehypertensive TOHP partici-
pants characterized by a median of 5 24-hour urine collec-
tions (range  =  1–7), 193 cardiovascular events occurred.31 
First events included 68 myocardial infarctions, 77 coro-
nary revascularizations, 22 strokes, and 27 cardiovascular 
deaths.31 In fully adjusted models accounting for clinic, 
treatment assignment, demographic variables, baseline 
covariables, and changes in weight, smoking, and exer-
cise, there was a nonsignificant trend of increasing risk 
with higher sodium excretion. Compared with those with 
sodium excretion ranging from 3,600 mg/day (157  mmol/
day) to 4,800 mg/day (209  mmol/day), the risk for those 
with sodium <2,300 mg/d was 32% lower (P = 0.13). When 
sodium was considered as a continuous term, risk increased 
by 17% per 1,000 mg/day (43 mmol/day) increase in sodium, 
but as for the categorical analysis, the P value did not reach 
formal significance (P = 0.054).31 The compelling evidence 
in the TOHP report31 was therefore based on nonsignificant 
or borderline P values.
The Institute of Medicine assessment
Statistical modeling led to the belief that modest reduc-
tions in dietary salt intake could substantially reduce 
cardiovascular events and medical costs.32,33 Short-term 
intervention studies in human normotensive volunteers5,6 
or hypertensive patients5,6 or even chimpanzees34 cannot be 
reasonably extrapolated to the long-term exposure of the 
general population to salt. The recent Institute of Medicine 
(IOM) report, “Sodium Intake in Populations: Assessment of 
Evidence,”35 failed to find robust evidence to support current 
guidelines promoted by the US Centers for Disease Control 
and Prevention,36 the New York City Department of Health 
and Mental Hygiene,37 or the American Heart Association38 
to reduce sodium intake population-wide from the current 
3,400 mg/day (148 mmol/day) to <2,300 mg/day (100 mmol/
day) and, for half of the US population at increased cardio-
vascular risk, to <1,500 mg/day (65  mmol/day). The IOM 
recognized heterogeneity of results among observational and 
experimental studies, baseline level of blood pressure and 
sodium intake being the major determinants of the blood 
pressure responses to sodium restriction.35 Furthermore, 
the IOM cautioned against sodium intakes <1,500 mg/day 
(65  mmol/day).35 Of US adults, only 9% currently con-
sume <2,300 mg/day and just 0.6% have a sodium intake 
<1,500 mg/day,39 rendering the ban on salt,38 if at all feasi-
ble,4 the most aggressive lifestyle intervention ever planned 
in the history of mankind. These low-salt goals should be 
reached by 202040 without being substantiated by large rand-
omized clinical trials proving benefit in terms of hard cardi-
ovascular outcomes and without questioning feasibility and 
acceptance by the general public. The guidelines36–38 thereby 
completely disregard potential harm caused by the exponen-
tial activation of the renin-angiotensin-aldosterone system41 
and the sympathetic nervous system42 by adverse changes 
in serum lipids43 or by increasing insulin resistance44 once 
24-hour urinary sodium excretion drops to <100  mmol/
day. The activation of sodium conserving mechanisms at 
intakes <100  mmol/day41–43 and the strong dependence of 
any blood pressure responses on the baseline level45 make a 
linear dose–response curve as postulated by the guidelines38 
or extrapolations32,33 unlikely. Graudal et  al.’s meta-anal-
ysis, in fact, showed a U-shaped relation.1 The meta-anal-
ysis included NHANES I46 and III47 data. Substituting the 
NHANES data used by Graudal et al.1 with more recent anal-
yses published by other investigators25,48 resulted in a rela-
tive risk of total mortality for low vs. usual sodium of 1.01 
(95% CI = 0.90–1.14). However, the number of participants 
retained in the analyses (n = 11,346 vs. n = 9,485)46,48 and the 
number of deaths (n = 3,923 vs. n = 2,486)46,48 were higher 
in the first compared with the repeat analysis of NHANES 
I, whereas the opposite was the case for the first compared 
with the repeat analysis of NHANES III (participants ana-
lyzed: 8,699 vs. 12,267; deaths: 1,150 vs. 2,270; follow-up: 
8.7 vs. 14.8 years).25,47 Graudal et al.’s meta-analysis did not 
include the TOHP cohort observational analysis31 published 
online in January 2014 and in print 3 months later.
Several publications authored by experts at the other side 
of salt debate, including a semiquantitative review,15 high-
lighted the challenges of interpreting observational reports 
on the relation between cardiovascular disease and salt 
intake. However, for now, in the absence of randomized 
clinical trials powered to study the long-term cardiovascular 
health outcomes in relation to different levels of salt intake, 
observational studies remain a major source of informa-
tion in spite of possible pitfalls.15 Expert committees writ-
ing salt guidelines36–38 argue that all relevant research should 
be considered and weighed appropriately, in particular the 
intervention studies in normotensive5,6 and hypertensive5,6 
volunteers and the mainly observational28 and ecological18,49 
studies showing association between stroke and salt intake.
Conclusions
Graudal et  al.’s meta-analysis solidifies the evidence 
from previous studies3,10–13 and extends the IOM report35 
by identifying a specific range of sodium intake (2,645–
4,945 mg/day) associated with the most favorable health 
outcomes—within which variation in sodium intake is 
not associated with variation in mortality. Moreover, this 
optimal range of intake, based upon currently available evi-
dence, is corresponding with the dietary intake of most of 
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IOM rules for definition of an adequate sodium intake and 
an upper tolerable sodium level.51 For science to advance, 
from time-to-time, medical textbooks and dogma’s need 
a Copernican revolution. Perhaps the time has come for 
the advocates of the worldwide action on salt to reconsider 
their salt-centric point of view of the healthcare cosmos. 
A  similar paradigm shift in the management of compen-
sated52 and decompensated53,54 heart failure is currently 
unfolding.
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